A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery.

Autor: Vaughan HJ; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Est-Witte S; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Dockery LT; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Urello MA; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Boyd J; Discovery Sciences, BioPharma R&D, AstraZeneca, Gaithersburg, MD, USA., Keyser BD; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Zhuang L; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Marelli M; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Christie RJ; Biologics Engineering, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.

Publikováno v: Science and technology of advanced materials [Sci Technol Adv Mater] 2024 May 13; Vol. 25 (1), pp. 2351791. Date of Electronic Publication: 2024 May 13 (Print Publication: 2024).